Ligand source activities (1 row/activity)



Get vendors


Ligands Receptor Assay information Chemical information
Sel. page Common
name		 GPCRdb ID #Vendors Reference
ligand		 Fold selectivity
(Potency)		 # tested GPCRs
(Potency)		 Species p-value
(-log)		 Type Activity
Relation		 Activity
Value		 Assay Type Assay Description Source Mol
weight		 Rot
Bonds		 H don H acc LogP Smiles DOI
10180382 110060 0 None 1 2 Human 5.9 pEC50 = 5.9 Functional
Agonistic activity against lysophosphatidic acid receptor 1 receptor using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 receptor using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 419 19 4 3 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(O)P(=O)(O)O 10.1016/j.bmcl.2004.04.061
CHEMBL325288 110060 0 None 1 2 Human 5.9 pEC50 = 5.9 Functional
Agonistic activity against lysophosphatidic acid receptor 1 receptor using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 receptor using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 419 19 4 3 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(O)P(=O)(O)O 10.1016/j.bmcl.2004.04.061
156020178 177544 0 None - 1 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 446 20 2 5 5.1 CCCCCC/C=C\CCCCCCCC(=O)OC[C@H](CC(F)(C(=O)O)C(=O)O)OC 10.1021/acs.jmedchem.9b01287
CHEMBL4648374 177544 0 None - 1 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 446 20 2 5 5.1 CCCCCC/C=C\CCCCCCCC(=O)OC[C@H](CC(F)(C(=O)O)C(=O)O)OC 10.1021/acs.jmedchem.9b01287
5311263 4078 18 None -10 7 Human 7.8 pEC50 = 7.8 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1016/j.bmcl.2004.04.061
CHEMBL117021 4078 18 None -10 7 Human 7.8 pEC50 = 7.8 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1016/j.bmcl.2004.04.061
156013745 176683 0 None - 1 Human 5.8 pEC50 = 5.8 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 442 18 1 5 5.7 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H]1CC(F)(C(=O)O)C(=O)O1 10.1021/acs.jmedchem.9b01287
CHEMBL4636192 176683 0 None - 1 Human 5.8 pEC50 = 5.8 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 442 18 1 5 5.7 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H]1CC(F)(C(=O)O)C(=O)O1 10.1021/acs.jmedchem.9b01287
6610239 67258 24 None -1 2 Human 5.7 pEC50 = 5.7 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 423 19 4 4 4.1 CCCCCCCCCCCCCCCC(=O)N[C@@H](COP(=O)(O)O)C(=O)O 10.1021/jm049609r
CHEMBL190328 67258 24 None -1 2 Human 5.7 pEC50 = 5.7 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 423 19 4 4 4.1 CCCCCCCCCCCCCCCC(=O)N[C@@H](COP(=O)(O)O)C(=O)O 10.1021/jm049609r
156011290 176790 0 None - 1 Human 4.7 pEC50 = 4.7 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 520 19 3 5 6.2 O=C(CCCCCCCCCCCCc1ccc(-c2ccccc2)cc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4637898 176790 0 None - 1 Human 4.7 pEC50 = 4.7 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 520 19 3 5 6.2 O=C(CCCCCCCCCCCCc1ccc(-c2ccccc2)cc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
11473989 66770 0 None 1 3 Human 6.7 pEC50 = 6.7 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 364 17 2 2 6.3 CCCCCCCC/C=C/CCCCCCCCOP(O)(O)=S 10.1021/jm049609r
CHEMBL187459 66770 0 None 1 3 Human 6.7 pEC50 = 6.7 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 364 17 2 2 6.3 CCCCCCCC/C=C/CCCCCCCCOP(O)(O)=S 10.1021/jm049609r
44344023 112824 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 403 19 3 2 5.7 CCCCCCCC/C=C\CCCCCCCC(=O)NCCCP(=O)(O)O 10.1016/j.bmcl.2004.04.061
CHEMBL331661 112824 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 403 19 3 2 5.7 CCCCCCCC/C=C\CCCCCCCC(=O)NCCCP(=O)(O)O 10.1016/j.bmcl.2004.04.061
44343825 10943 16 None -6 2 Human 6.7 pEC50 = 6.7 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 405 19 3 3 5.2 CCCCCCCC/C=C\CCCCCCCC(=O)NCCOP(=O)(O)O 10.1016/j.bmcl.2004.04.061
CHEMBL117754 10943 16 None -6 2 Human 6.7 pEC50 = 6.7 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 405 19 3 3 5.2 CCCCCCCC/C=C\CCCCCCCC(=O)NCCOP(=O)(O)O 10.1016/j.bmcl.2004.04.061
5283533 176509 1 None - 1 Human 5.7 pEC50 = 5.7 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 422 19 3 5 4.6 CCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4633208 176509 1 None - 1 Human 5.7 pEC50 = 5.7 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 422 19 3 5 4.6 CCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156016950 177170 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 388 14 3 5 3.0 O=C(CCCCCCCCc1ccccc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4642688 177170 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 388 14 3 5 3.0 O=C(CCCCCCCCc1ccccc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
10136738 10909 0 None 5 2 Human 6.7 pEC50 = 6.7 Functional
Agonist activity at LPA1R (unknown origin) by [35S]GTPgammaS binding assayAgonist activity at LPA1R (unknown origin) by [35S]GTPgammaS binding assay
ChEMBL 417 19 3 3 5.2 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=O)P(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL117529 10909 0 None 5 2 Human 6.7 pEC50 = 6.7 Functional
Agonist activity at LPA1R (unknown origin) by [35S]GTPgammaS binding assayAgonist activity at LPA1R (unknown origin) by [35S]GTPgammaS binding assay
ChEMBL 417 19 3 3 5.2 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=O)P(=O)(O)O 10.1021/acs.jmedchem.9b01287
10136738 10909 0 None 5 2 Human 6.7 pEC50 = 6.7 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 417 19 3 3 5.2 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=O)P(=O)(O)O 10.1016/j.bmcl.2004.04.061
CHEMBL117529 10909 0 None 5 2 Human 6.7 pEC50 = 6.7 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 417 19 3 3 5.2 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=O)P(=O)(O)O 10.1016/j.bmcl.2004.04.061
10587 3833 1 None - 1 Human 6.6 pEC50 = 6.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 BrC[C@@H](OC(=O)CCCCCCCCCc1ccccc1)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
145996523 3833 1 None - 1 Human 6.6 pEC50 = 6.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 BrC[C@@H](OC(=O)CCCCCCCCCc1ccccc1)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4646737 3833 1 None - 1 Human 6.6 pEC50 = 6.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 BrC[C@@H](OC(=O)CCCCCCCCCc1ccccc1)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156017427 177186 0 None - 1 Human 6.6 pEC50 = 6.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 O=C(CCCCCCCCCc1ccccc1)OC(CBr)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4642952 177186 0 None - 1 Human 6.6 pEC50 = 6.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 O=C(CCCCCCCCCc1ccccc1)OC(CBr)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156017791 177232 0 None - 1 Human 4.6 pEC50 = 4.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 O=C(CCCCCCCCCc1ccccc1)O[C@@H](CBr)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4643694 177232 0 None - 1 Human 4.6 pEC50 = 4.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 O=C(CCCCCCCCCc1ccccc1)O[C@@H](CBr)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
52929768 177470 0 None - 1 Human 5.6 pEC50 = 5.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 380 16 3 5 3.5 CCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4647245 177470 0 None - 1 Human 5.6 pEC50 = 5.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 380 16 3 5 3.5 CCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
5311263 4078 18 None -10 7 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at LPA1 expressed in human chem1 cells assessed as intracellular calcium mobilization by FLIPR assayAgonist activity at LPA1 expressed in human chem1 cells assessed as intracellular calcium mobilization by FLIPR assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1016/j.bmc.2009.12.020
CHEMBL117021 4078 18 None -10 7 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at LPA1 expressed in human chem1 cells assessed as intracellular calcium mobilization by FLIPR assayAgonist activity at LPA1 expressed in human chem1 cells assessed as intracellular calcium mobilization by FLIPR assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1016/j.bmc.2009.12.020
44343851 110174 0 None - 1 Human 6.5 pEC50 = 6.5 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 433 19 3 3 6.0 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=S)P(=O)(O)O 10.1016/j.bmcl.2004.04.061
CHEMBL325970 110174 0 None - 1 Human 6.5 pEC50 = 6.5 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 433 19 3 3 6.0 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=S)P(=O)(O)O 10.1016/j.bmcl.2004.04.061
156011890 176757 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 498 20 2 4 6.4 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@H](CBr)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4637403 176757 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 498 20 2 4 6.4 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@H](CBr)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156019757 177363 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 416 16 3 5 3.8 O=C(CCCCCCCCCCc1ccccc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4645684 177363 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 416 16 3 5 3.8 O=C(CCCCCCCCCCc1ccccc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156018702 177311 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 478 16 3 5 5.0 O=C(CCCCCCCCCc1ccc(-c2ccccc2)cc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4644847 177311 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 478 16 3 5 5.0 O=C(CCCCCCCCCc1ccc(-c2ccccc2)cc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
5311263 4078 18 None -10 7 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human LPA1 expressed in LPA1xLPA2 double knockout mouse MEF cells up to 10 uM by Fura-2AM dye based Ca2+ mobilization assayAgonist activity at human LPA1 expressed in LPA1xLPA2 double knockout mouse MEF cells up to 10 uM by Fura-2AM dye based Ca2+ mobilization assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/jm5007116
CHEMBL117021 4078 18 None -10 7 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human LPA1 expressed in LPA1xLPA2 double knockout mouse MEF cells up to 10 uM by Fura-2AM dye based Ca2+ mobilization assayAgonist activity at human LPA1 expressed in LPA1xLPA2 double knockout mouse MEF cells up to 10 uM by Fura-2AM dye based Ca2+ mobilization assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/jm5007116
44159681 176479 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 450 21 3 5 5.4 CCCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4632820 176479 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 450 21 3 5 5.4 CCCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
129836 177422 19 None - 1 Human 5.4 pEC50 = 5.4 Functional
Agonist activity at recombinant human full-length LPA1 receptor expressed in dhfr- deficient CHO cells assessed as increase in intracellular calcium flux measured for 1 min by fluo-3AM dye based FLIPR assayAgonist activity at recombinant human full-length LPA1 receptor expressed in dhfr- deficient CHO cells assessed as increase in intracellular calcium flux measured for 1 min by fluo-3AM dye based FLIPR assay
ChEMBL 254 0 1 1 3.7 CC1CCC2(C)c3[nH]c4ccccc4c3CCN2C1 10.1021/acs.jmedchem.9b01287
CHEMBL4646443 177422 19 None - 1 Human 5.4 pEC50 = 5.4 Functional
Agonist activity at recombinant human full-length LPA1 receptor expressed in dhfr- deficient CHO cells assessed as increase in intracellular calcium flux measured for 1 min by fluo-3AM dye based FLIPR assayAgonist activity at recombinant human full-length LPA1 receptor expressed in dhfr- deficient CHO cells assessed as increase in intracellular calcium flux measured for 1 min by fluo-3AM dye based FLIPR assay
ChEMBL 254 0 1 1 3.7 CC1CCC2(C)c3[nH]c4ccccc4c3CCN2C1 10.1021/acs.jmedchem.9b01287
44343866 10973 0 None 2 2 Human 7.4 pEC50 = 7.4 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 433 19 3 3 5.4 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=O)P(O)(O)=S 10.1016/j.bmcl.2004.04.061
CHEMBL117798 10973 0 None 2 2 Human 7.4 pEC50 = 7.4 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 433 19 3 3 5.4 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=O)P(O)(O)=S 10.1016/j.bmcl.2004.04.061
52929751 177204 0 None - 1 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 408 18 3 5 4.3 CCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4643262 177204 0 None - 1 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 408 18 3 5 4.3 CCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156011219 176704 0 None - 1 Human 6.3 pEC50 = 6.3 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 402 15 3 5 3.4 O=C(CCCCCCCCCc1ccccc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4636453 176704 0 None - 1 Human 6.3 pEC50 = 6.3 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 402 15 3 5 3.4 O=C(CCCCCCCCCc1ccccc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156021731 177529 0 None - 1 Human 5.3 pEC50 = 5.3 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 445 20 3 4 4.6 CCCCCC/C=C\CCCCCCCC(=O)NC[C@H](CC(F)(C(=O)O)C(=O)O)OC 10.1021/acs.jmedchem.9b01287
CHEMBL4648051 177529 0 None - 1 Human 5.3 pEC50 = 5.3 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 445 20 3 4 4.6 CCCCCC/C=C\CCCCCCCC(=O)NC[C@H](CC(F)(C(=O)O)C(=O)O)OC 10.1021/acs.jmedchem.9b01287
2913 344 0 None -8 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysisAgonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysis
ChEMBL 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC 10.1039/C4MD00333K
56947064 344 0 None -8 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysisAgonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysis
ChEMBL 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC 10.1039/C4MD00333K
CHEMBL3621962 344 0 None -8 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysisAgonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysis
ChEMBL 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC 10.1039/C4MD00333K
156020199 177556 0 None - 1 Human 5.2 pEC50 = 5.2 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 474 22 2 5 5.9 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](CC(F)(C(=O)O)C(=O)O)OC 10.1021/acs.jmedchem.9b01287
CHEMBL4648653 177556 0 None - 1 Human 5.2 pEC50 = 5.2 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 474 22 2 5 5.9 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](CC(F)(C(=O)O)C(=O)O)OC 10.1021/acs.jmedchem.9b01287
122191543 123171 0 None -12 2 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysisAgonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysis
ChEMBL 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@H](COP(O)(O)=S)OC 10.1039/C4MD00333K
CHEMBL3621961 123171 0 None -12 2 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysisAgonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysis
ChEMBL 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@H](COP(O)(O)=S)OC 10.1039/C4MD00333K
2906 2313 14 None -10 12 Human 7.1 pEC50 = 7.1 Functional
Agonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 10.1021/acs.jmedchem.6b01270
5395 2313 14 None -10 12 Human 7.1 pEC50 = 7.1 Functional
Agonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 10.1021/acs.jmedchem.6b01270
5497152 2313 14 None -10 12 Human 7.1 pEC50 = 7.1 Functional
Agonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 10.1021/acs.jmedchem.6b01270
CHEMBL1222042 2313 14 None -10 12 Human 7.1 pEC50 = 7.1 Functional
Agonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 10.1021/acs.jmedchem.6b01270
5311263 4078 18 None -10 7 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL117021 4078 18 None -10 7 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
11317548 161808 7 None - 1 Human 9.8 pIC50 = 9.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by LPA stimulation measured after 3 mins by fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by LPA stimulation measured after 3 mins by fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4165205 161808 7 None - 1 Human 9.8 pIC50 = 9.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by LPA stimulation measured after 3 mins by fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by LPA stimulation measured after 3 mins by fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4175820 161808 7 None - 1 Human 9.8 pIC50 = 9.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by LPA stimulation measured after 3 mins by fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by LPA stimulation measured after 3 mins by fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
11317548 161808 7 None - 1 Human 9.7 pIC50 = 9.7 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by compound washout and subsequent LPA stimulation measured after 3 mins by fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by compound washout and subsequent LPA stimulation measured after 3 mins by fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4165205 161808 7 None - 1 Human 9.7 pIC50 = 9.7 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by compound washout and subsequent LPA stimulation measured after 3 mins by fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by compound washout and subsequent LPA stimulation measured after 3 mins by fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4175820 161808 7 None - 1 Human 9.7 pIC50 = 9.7 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by compound washout and subsequent LPA stimulation measured after 3 mins by fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by compound washout and subsequent LPA stimulation measured after 3 mins by fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
71265339 82684 17 None - 1 Human 7.0 pIC50 = 7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 482 7 2 6 5.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
CHEMBL2182029 82684 17 None - 1 Human 7.0 pIC50 = 7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 482 7 2 6 5.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
11236547 93239 0 None 1 2 Rat 7.0 pIC50 = 7 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CCSCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246942 93239 0 None 1 2 Rat 7.0 pIC50 = 7 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CCSCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
66774612 150191 0 None 229 2 Human 7.0 pIC50 = 7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 477 12 1 5 4.8 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(OCC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3956307 150191 0 None 229 2 Human 7.0 pIC50 = 7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 477 12 1 5 4.8 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(OCC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
134156371 153796 0 None - 1 Human 7.0 pIC50 = 7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cccc(C)c3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3986868 153796 0 None - 1 Human 7.0 pIC50 = 7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cccc(C)c3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
44414925 77713 0 None 72 2 Human 7.0 pIC50 = 7.0 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 436 18 1 4 7.1 CCCCCCCCCCCCCCCCCC(=O)OC[C@@H]1CC(F)P(=O)(O)O1 10.1021/jm060351+
CHEMBL210117 77713 0 None 72 2 Human 7.0 pIC50 = 7.0 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 436 18 1 4 7.1 CCCCCCCCCCCCCCCCCC(=O)OC[C@@H]1CC(F)P(=O)(O)O1 10.1021/jm060351+
70819309 82682 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 447 7 2 5 5.5 CC(C)[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C 10.1021/jm301022v
CHEMBL2182025 82682 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 447 7 2 5 5.5 CC(C)[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C 10.1021/jm301022v
44325391 205192 0 None -30 2 Human 6.0 pIC50 = 6.0 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL91058 205192 0 None -30 2 Human 6.0 pIC50 = 6.0 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
10393842 168622 0 None 1 2 Human 7.0 pIC50 = 7.0 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL440696 168622 0 None 1 2 Human 7.0 pIC50 = 7.0 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
11409276 148200 0 None 2 2 Rat 7.0 pIC50 = 7.0 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 492 9 2 7 4.7 CC(OC(=O)Nc1conc1-c1ccc(CS(=O)(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL394038 148200 0 None 2 2 Rat 7.0 pIC50 = 7.0 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 492 9 2 7 4.7 CC(OC(=O)Nc1conc1-c1ccc(CS(=O)(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
73336174 113500 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 341 5 1 8 1.9 COc1ccc(C(=O)/C(=N\C(C)C)n2ncc(C#N)c2N)c(OC)c1 10.1016/j.bmcl.2014.08.001
CHEMBL3326534 113500 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 341 5 1 8 1.9 COc1ccc(C(=O)/C(=N\C(C)C)n2ncc(C#N)c2N)c(OC)c1 10.1016/j.bmcl.2014.08.001
71453959 82687 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1C(F)(F)F 10.1021/jm301022v
CHEMBL2182031 82687 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1C(F)(F)F 10.1021/jm301022v
44441096 93189 0 None 3 2 Rat 6.9 pIC50 = 6.9 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 470 9 2 5 6.7 CC(OC(=O)Nc1conc1-c1ccc(CCC(C)(C)CC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246734 93189 0 None 3 2 Rat 6.9 pIC50 = 6.9 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 470 9 2 5 6.7 CC(OC(=O)Nc1conc1-c1ccc(CCC(C)(C)CC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
140083418 162560 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 437 11 2 5 4.9 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(C(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4177410 162560 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 437 11 2 5 4.9 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(C(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
66775429 150534 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 449 9 1 2 6.3 O=C(O)c1ccccc1-c1ccc(CN(CCCc2ccccc2)C(=O)c2ccccc2)cc1 10.1021/acsmedchemlett.6b00225
CHEMBL3959003 150534 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 449 9 1 2 6.3 O=C(O)c1ccccc1-c1ccc(CN(CCCc2ccccc2)C(=O)c2ccccc2)cc1 10.1021/acsmedchemlett.6b00225
66863259 162072 0 None - 1 Human 7.9 pIC50 = 7.9 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 451 12 2 5 4.8 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4169559 162072 0 None - 1 Human 7.9 pIC50 = 7.9 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 451 12 2 5 4.8 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
66775552 147267 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 555 13 1 6 6.5 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccccc3C(=O)O)cc2)cc(OC)c1OC 10.1021/acsmedchemlett.6b00225
CHEMBL3932828 147267 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 555 13 1 6 6.5 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccccc3C(=O)O)cc2)cc(OC)c1OC 10.1021/acsmedchemlett.6b00225
122191545 123174 0 None 17 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 1 min followed by LPA induction measured for 15 secs by Fura-2 AM probe-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 1 min followed by LPA induction measured for 15 secs by Fura-2 AM probe-based fluorometric analysis
ChEMBL 446 8 2 6 5.6 CC(OC(=O)Nc1cnoc1-c1ccc(CSCC(=O)O)cc1)c1ccccc1Cl 10.1039/C4MD00333K
CHEMBL3621965 123174 0 None 17 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 1 min followed by LPA induction measured for 15 secs by Fura-2 AM probe-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 1 min followed by LPA induction measured for 15 secs by Fura-2 AM probe-based fluorometric analysis
ChEMBL 446 8 2 6 5.6 CC(OC(=O)Nc1cnoc1-c1ccc(CSCC(=O)O)cc1)c1ccccc1Cl 10.1039/C4MD00333K
11236547 93239 0 None -1 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CCSCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246942 93239 0 None -1 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CCSCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
11316893 93428 0 None -4 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 450 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCC1 10.1016/j.bmcl.2007.04.024
CHEMBL247959 93428 0 None -4 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 450 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCC1 10.1016/j.bmcl.2007.04.024
66774300 145101 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 10 1 3 6.3 COc1cccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3915800 145101 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 10 1 3 6.3 COc1cccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
134145238 150190 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 525 12 1 5 6.5 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cccc(C(=O)O)c3)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3956293 150190 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 525 12 1 5 6.5 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cccc(C(=O)O)c3)cc2)c1 10.1021/acsmedchemlett.6b00225
134156710 153553 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3c(C)cccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3984953 153553 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3c(C)cccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
11167018 93190 0 None -1 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 457 8 3 6 5.1 CC(OC(=O)Nc1conc1-c1ccc(NC(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246735 93190 0 None -1 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 457 8 3 6 5.1 CC(OC(=O)Nc1conc1-c1ccc(NC(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
132191135 157499 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAntagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 468 4 1 4 3.7 O=C(Nc1cc(F)c(F)c(F)c1)c1cc(S(=O)(=O)N2CCOCC2)c(Cl)cc1Cl 10.1021/acs.jmedchem.6b01270
CHEMBL4085965 157499 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAntagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 468 4 1 4 3.7 O=C(Nc1cc(F)c(F)c(F)c1)c1cc(S(=O)(=O)N2CCOCC2)c(Cl)cc1Cl 10.1021/acs.jmedchem.6b01270
66774778 145279 0 None - 1 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cc(C)ccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3917128 145279 0 None - 1 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cc(C)ccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
46213949 370 39 None 5 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 10.1021/jm301022v
6988 370 39 None 5 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 10.1021/jm301022v
CHEMBL2182052 370 39 None 5 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 10.1021/jm301022v
122191544 123173 0 None -5 4 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization by Fura-2 AM probe-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization by Fura-2 AM probe-based fluorometric analysis
ChEMBL 484 18 3 4 5.4 CCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)CC(Br)P(=O)(O)O 10.1039/C4MD00333K
CHEMBL3621964 123173 0 None -5 4 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization by Fura-2 AM probe-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization by Fura-2 AM probe-based fluorometric analysis
ChEMBL 484 18 3 4 5.4 CCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)CC(Br)P(=O)(O)O 10.1039/C4MD00333K
10367662 2146 82 None -1 5 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/jm301022v
2907 2146 82 None -1 5 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/jm301022v
CHEMBL361501 2146 82 None -1 5 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/jm301022v
10367662 2146 82 None 1 5 Rat 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmcl.2007.04.024
2907 2146 82 None 1 5 Rat 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmcl.2007.04.024
CHEMBL361501 2146 82 None 1 5 Rat 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmcl.2007.04.024
66775043 2879 29 None 53 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 461 11 1 4 4.9 COc1cc(cc(c1C)OC)C(=O)N(Cc1ccc(cc1)CC(=O)O)CCCc1ccccc1 10.1021/acsmedchemlett.6b00225
9499 2879 29 None 53 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 461 11 1 4 4.9 COc1cc(cc(c1C)OC)C(=O)N(Cc1ccc(cc1)CC(=O)O)CCCc1ccccc1 10.1021/acsmedchemlett.6b00225
CHEMBL3941037 2879 29 None 53 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 461 11 1 4 4.9 COc1cc(cc(c1C)OC)C(=O)N(Cc1ccc(cc1)CC(=O)O)CCCc1ccccc1 10.1021/acsmedchemlett.6b00225
66775043 2879 29 None 53 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 461 11 1 4 4.9 COc1cc(cc(c1C)OC)C(=O)N(Cc1ccc(cc1)CC(=O)O)CCCc1ccccc1 10.1021/acsmedchemlett.7b00383
9499 2879 29 None 53 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 461 11 1 4 4.9 COc1cc(cc(c1C)OC)C(=O)N(Cc1ccc(cc1)CC(=O)O)CCCc1ccccc1 10.1021/acsmedchemlett.7b00383
CHEMBL3941037 2879 29 None 53 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 461 11 1 4 4.9 COc1cc(cc(c1C)OC)C(=O)N(Cc1ccc(cc1)CC(=O)O)CCCc1ccccc1 10.1021/acsmedchemlett.7b00383
71457478 82691 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 460 7 2 6 5.1 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC(C)C1CCC1 10.1021/jm301022v
CHEMBL2182035 82691 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 460 7 2 6 5.1 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC(C)C1CCC1 10.1021/jm301022v
2905 386 41 None -1 7 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysis
ChEMBL 490 7 2 5 6.9 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C 10.1039/C4MD00333K
46240292 386 41 None -1 7 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysis
ChEMBL 490 7 2 5 6.9 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C 10.1039/C4MD00333K
CHEMBL3621966 386 41 None -1 7 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysis
ChEMBL 490 7 2 5 6.9 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C 10.1039/C4MD00333K
71457480 82701 0 None 2 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
CHEMBL2182046 82701 0 None 2 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
11305821 93240 0 None -3 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 464 9 2 6 6.1 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCCC1 10.1016/j.bmcl.2007.04.024
CHEMBL246943 93240 0 None -3 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 464 9 2 6 6.1 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCCC1 10.1016/j.bmcl.2007.04.024
23080067 143464 0 None - 1 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 463 9 1 2 6.6 Cc1cccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3902849 143464 0 None - 1 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 463 9 1 2 6.6 Cc1cccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
71455702 82688 0 None 39 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
CHEMBL2182032 82688 0 None 39 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
71457483 82706 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 321 4 1 4 4.4 C[C@@H](OC(=O)Nc1c(-c2ccccc2)cnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182053 82706 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 321 4 1 4 4.4 C[C@@H](OC(=O)Nc1c(-c2ccccc2)cnn1C)c1ccccc1 10.1021/jm301022v
71459352 82683 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 431 6 2 5 5.0 Cn1ncc(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC1CCC1 10.1021/jm301022v
CHEMBL2182026 82683 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 431 6 2 5 5.0 Cn1ncc(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC1CCC1 10.1021/jm301022v
70856266 82698 0 None 120 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182043 82698 0 None 120 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
71455703 82699 0 None 1445 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 500 7 2 6 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2F)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182044 82699 0 None 1445 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 500 7 2 6 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2F)nnn1C)c1ccccc1 10.1021/jm301022v
70856266 82698 0 None 120 2 Human 7.8 pIC50 = 7.8 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1ccccc1 nan
CHEMBL2182043 82698 0 None 120 2 Human 7.8 pIC50 = 7.8 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1ccccc1 nan
71455703 82699 0 None 1445 2 Human 7.8 pIC50 = 7.8 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 500 7 2 6 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2F)nnn1C)c1ccccc1 nan
CHEMBL2182044 82699 0 None 1445 2 Human 7.8 pIC50 = 7.8 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 500 7 2 6 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2F)nnn1C)c1ccccc1 nan
71457480 82701 0 None 2 2 Human 7.8 pIC50 = 7.8 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 550 7 2 6 6.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
CHEMBL2182046 82701 0 None 2 2 Human 7.8 pIC50 = 7.8 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 550 7 2 6 6.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
71452129 82703 0 None 120 2 Human 7.7 pIC50 = 7.7 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 559 8 2 8 4.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1ccccc1 nan
CHEMBL2182049 82703 0 None 120 2 Human 7.7 pIC50 = 7.7 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 559 8 2 8 4.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1ccccc1 nan
66862638 162497 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 452 12 2 6 4.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2cnc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4176330 162497 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 452 12 2 6 4.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2cnc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
132191134 155300 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAntagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 500 4 1 4 4.7 O=C(Nc1cc(Cl)c(F)c(Cl)c1)c1cc(S(=O)(=O)N2CCOCC2)c(Cl)cc1Cl 10.1021/acs.jmedchem.6b01270
CHEMBL4060128 155300 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAntagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 500 4 1 4 4.7 O=C(Nc1cc(Cl)c(F)c(Cl)c1)c1cc(S(=O)(=O)N2CCOCC2)c(Cl)cc1Cl 10.1021/acs.jmedchem.6b01270
71452129 82703 0 None 120 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 559 8 2 8 4.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182049 82703 0 None 120 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 559 8 2 8 4.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
66774667 143328 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 11 1 4 5.1 COc1cc(C(=O)N(CCCc2cccc(F)c2)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3901754 143328 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 11 1 4 5.1 COc1cc(C(=O)N(CCCc2cccc(F)c2)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
70856266 82698 0 None 120 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182043 82698 0 None 120 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
71455703 82699 0 None 1445 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 500 7 2 6 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2F)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182044 82699 0 None 1445 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 500 7 2 6 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2F)nnn1C)c1ccccc1 10.1021/jm301022v
66553162 82712 1 None 407 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 481 7 2 5 6.2 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182063 82712 1 None 407 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 481 7 2 5 6.2 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccccc1 10.1021/jm301022v
44441093 93138 0 None -2 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 442 9 2 5 6.1 CC(OC(=O)Nc1conc1-c1ccc(CCCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246527 93138 0 None -2 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 442 9 2 5 6.1 CC(OC(=O)Nc1conc1-c1ccc(CCCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
66553162 82712 1 None 407 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 481 7 2 5 6.2 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182063 82712 1 None 407 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 481 7 2 5 6.2 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccccc1 10.1021/jm301022v
66773977 150569 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 523 12 1 4 6.3 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3CC(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3959223 150569 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 523 12 1 4 6.3 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3CC(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
71462861 82689 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 448 7 2 6 5.0 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)C(C)C 10.1021/jm301022v
CHEMBL2182033 82689 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 448 7 2 6 5.0 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)C(C)C 10.1021/jm301022v
118067342 159872 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 399 5 0 5 4.1 C[C@@H](OC(=O)Cc1c(-c2ccc(Br)cc2)nnn1C)c1ccccc1 nan
CHEMBL4111515 159872 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 399 5 0 5 4.1 C[C@@H](OC(=O)Cc1c(-c2ccc(Br)cc2)nnn1C)c1ccccc1 nan
66861759 161639 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 465 13 2 5 5.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4162680 161639 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 465 13 2 5 5.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
71457482 82705 0 None 165 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 462 7 2 6 5.5 C[C@@H](OC(=O)Nc1c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182051 82705 0 None 165 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 462 7 2 6 5.5 C[C@@H](OC(=O)Nc1c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
744590 190632 27 None -10 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 304 6 4 4 0.8 O=C(O)/C=C/C(=O)Nc1cccc(NC(=O)/C=C/C(=O)O)c1 10.1016/j.bmc.2008.04.035
CHEMBL519002 190632 27 None -10 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 304 6 4 4 0.8 O=C(O)/C=C/C(=O)Nc1cccc(NC(=O)/C=C/C(=O)O)c1 10.1016/j.bmc.2008.04.035
744590 190632 27 None -10 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 304 6 4 4 0.8 O=C(O)/C=C/C(=O)Nc1cccc(NC(=O)/C=C/C(=O)O)c1 10.1016/j.bmc.2009.09.022
CHEMBL519002 190632 27 None -10 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 304 6 4 4 0.8 O=C(O)/C=C/C(=O)Nc1cccc(NC(=O)/C=C/C(=O)O)c1 10.1016/j.bmc.2009.09.022
66774701 148705 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 11 1 4 5.1 COc1cc(C(=O)N(CCCc2ccccc2F)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3944344 148705 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 11 1 4 5.1 COc1cc(C(=O)N(CCCc2ccccc2F)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
11374611 93231 0 None -4 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246929 93231 0 None -4 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
11312382 67005 1 None -21 3 Human 5.7 pIC50 = 5.7 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 292 13 2 2 4.6 CC/C=C/CCCCCCCCCCOP(=O)(O)O 10.1021/jm049609r
CHEMBL188591 67005 1 None -21 3 Human 5.7 pIC50 = 5.7 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 292 13 2 2 4.6 CC/C=C/CCCCCCCCCCOP(=O)(O)O 10.1021/jm049609r
155153661 171843 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 498 8 2 6 5.8 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cc2)c1CNC(=O)OCc1ccc(Cl)cc1 10.1021/acsmedchemlett.9b00429
CHEMBL4476814 171843 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 498 8 2 6 5.8 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cc2)c1CNC(=O)OCc1ccc(Cl)cc1 10.1021/acsmedchemlett.9b00429
71462862 82694 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 506 7 2 8 5.1 Cc1nnn(-c2ccc(-c3ccc(C4(c5nnn[nH]5)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
CHEMBL2182038 82694 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 506 7 2 8 5.1 Cc1nnn(-c2ccc(-c3ccc(C4(c5nnn[nH]5)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
11271067 162137 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 457 12 2 6 4.9 COc1cc([C@@H](O)[C@@H](CCCc2ccsc2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4170604 162137 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 457 12 2 6 4.9 COc1cc([C@@H](O)[C@@H](CCCc2ccsc2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
66774424 142640 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 537 13 1 4 6.7 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3CCC(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3896148 142640 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 537 13 1 4 6.7 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3CCC(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
82327 66808 13 None -5 2 Human 5.6 pIC50 = 5.6 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 294 14 2 2 4.8 CCCCCCCCCCCCCCOP(=O)(O)O 10.1021/jm049609r
CHEMBL187633 66808 13 None -5 2 Human 5.6 pIC50 = 5.6 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 294 14 2 2 4.8 CCCCCCCCCCCCCCOP(=O)(O)O 10.1021/jm049609r
71457481 82704 0 None 2 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 627 8 2 8 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
CHEMBL2182050 82704 0 None 2 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 627 8 2 8 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
71452130 82713 0 None 239 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 499 7 2 5 6.3 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccccc1F 10.1021/jm301022v
CHEMBL2182064 82713 0 None 239 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 499 7 2 5 6.3 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccccc1F 10.1021/jm301022v
71457481 82704 0 None 2 2 Human 7.6 pIC50 = 7.6 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 627 8 2 8 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
CHEMBL2182050 82704 0 None 2 2 Human 7.6 pIC50 = 7.6 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 627 8 2 8 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
10282223 3935 3 None -7 3 Human 5.6 pIC50 = 5.6 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](Cc1ccc(cc1)OCc1ccccc1)COP(=O)(O)O 10.1016/j.bmcl.2004.03.076
2909 3935 3 None -7 3 Human 5.6 pIC50 = 5.6 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](Cc1ccc(cc1)OCc1ccccc1)COP(=O)(O)O 10.1016/j.bmcl.2004.03.076
CHEMBL327240 3935 3 None -7 3 Human 5.6 pIC50 = 5.6 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](Cc1ccc(cc1)OCc1ccccc1)COP(=O)(O)O 10.1016/j.bmcl.2004.03.076
46213949 370 39 None 5 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysis
ChEMBL 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 10.1039/C4MD00333K
6988 370 39 None 5 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysis
ChEMBL 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 10.1039/C4MD00333K
CHEMBL2182052 370 39 None 5 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysis
ChEMBL 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 10.1039/C4MD00333K
71265339 82684 17 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 482 7 2 6 5.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
CHEMBL2182029 82684 17 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 482 7 2 6 5.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
11393306 67063 1 None -1 2 Human 5.6 pIC50 = 5.6 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 328 14 2 1 5.8 CCCCCCCCCCCCCCC(F)(F)P(=O)(O)O 10.1021/jm049609r
CHEMBL188859 67063 1 None -1 2 Human 5.6 pIC50 = 5.6 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 328 14 2 1 5.8 CCCCCCCCCCCCCCC(F)(F)P(=O)(O)O 10.1021/jm049609r
66773650 141908 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 477 9 1 2 6.9 Cc1cc(C)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3890162 141908 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 477 9 1 2 6.9 Cc1cc(C)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
66773644 147014 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 509 11 1 4 6.3 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3930834 147014 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 509 11 1 4 6.3 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
44441080 93230 0 None -3 2 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1cnoc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246928 93230 0 None -3 2 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1cnoc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
71455704 82702 0 None 2 2 Human 5.6 pIC50 = 5.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.6 C[C@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
CHEMBL2182047 82702 0 None 2 2 Human 5.6 pIC50 = 5.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.6 C[C@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
71455704 82702 0 None 2 2 Human 5.6 pIC50 = 5.6 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 550 7 2 6 6.6 C[C@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
CHEMBL2182047 82702 0 None 2 2 Human 5.6 pIC50 = 5.6 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 550 7 2 6 6.6 C[C@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
150134920 169891 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 501 8 2 7 4.8 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNC(=O)OCc1cc(F)cc(F)c1 10.1021/acsmedchemlett.9b00429
CHEMBL4448922 169891 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 501 8 2 7 4.8 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNC(=O)OCc1cc(F)cc(F)c1 10.1021/acsmedchemlett.9b00429
2260227 183495 9 None -3090 3 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 488 10 4 6 4.4 O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1 10.1016/j.bmc.2008.04.035
CHEMBL482498 183495 9 None -3090 3 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 488 10 4 6 4.4 O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1 10.1016/j.bmc.2008.04.035
2260227 183495 9 None -3090 3 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 488 10 4 6 4.4 O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1 10.1016/j.bmc.2009.09.022
CHEMBL482498 183495 9 None -3090 3 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 488 10 4 6 4.4 O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1 10.1016/j.bmc.2009.09.022
11409276 148200 0 None -2 2 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 492 9 2 7 4.7 CC(OC(=O)Nc1conc1-c1ccc(CS(=O)(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL394038 148200 0 None -2 2 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 492 9 2 7 4.7 CC(OC(=O)Nc1conc1-c1ccc(CS(=O)(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
75816 66822 50 None -7 3 Human 5.6 pIC50 = 5.6 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 266 12 2 2 4.0 CCCCCCCCCCCCOP(=O)(O)O 10.1021/jm049609r
CHEMBL187711 66822 50 None -7 3 Human 5.6 pIC50 = 5.6 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 266 12 2 2 4.0 CCCCCCCCCCCCOP(=O)(O)O 10.1021/jm049609r
11316893 93428 0 None 4 2 Rat 7.5 pIC50 = 7.5 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 450 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCC1 10.1016/j.bmcl.2007.04.024
CHEMBL247959 93428 0 None 4 2 Rat 7.5 pIC50 = 7.5 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 450 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCC1 10.1016/j.bmcl.2007.04.024
66862202 161722 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 457 12 2 6 4.9 COc1cc([C@@H](O)[C@@H](CCCc2cccs2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4164105 161722 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 457 12 2 6 4.9 COc1cc([C@@H](O)[C@@H](CCCc2cccs2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
44325401 105625 0 None -1 2 Human 5.5 pIC50 = 5.5 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 627 23 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OC2Cc3ccccc3C2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL313413 105625 0 None -1 2 Human 5.5 pIC50 = 5.5 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 627 23 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OC2Cc3ccccc3C2)cc1 10.1016/j.bmcl.2004.03.076
73335985 113494 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 385 3 1 6 3.2 N#Cc1cnn(/C(=N/C2CCCC2)C(=O)c2ccc(Br)cc2)c1N 10.1016/j.bmcl.2014.08.001
CHEMBL3326525 113494 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 385 3 1 6 3.2 N#Cc1cnn(/C(=N/C2CCCC2)C(=O)c2ccc(Br)cc2)c1N 10.1016/j.bmcl.2014.08.001
66774777 152505 0 None 229 2 Human 8.5 pIC50 = 8.5 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 573 12 1 5 7.4 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccc(Cl)cc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3975893 152505 0 None 229 2 Human 8.5 pIC50 = 8.5 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 573 12 1 5 7.4 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccc(Cl)cc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
66862629 161831 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 452 12 2 6 4.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2cc(CC(=O)O)cn2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4165714 161831 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 452 12 2 6 4.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2cc(CC(=O)O)cn2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
11197104 67269 1 None -31 3 Human 5.5 pIC50 = 5.5 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 292 13 2 2 4.6 CCCC/C=C/CCCCCCCCOP(=O)(O)O 10.1021/jm049609r
CHEMBL190430 67269 1 None -31 3 Human 5.5 pIC50 = 5.5 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 292 13 2 2 4.6 CCCC/C=C/CCCCCCCCOP(=O)(O)O 10.1021/jm049609r
71450322 82693 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 559 8 2 8 4.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
CHEMBL2182037 82693 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 559 8 2 8 4.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
66862841 162042 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 452 12 2 6 4.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CC(=O)O)n2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4169137 162042 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 452 12 2 6 4.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CC(=O)O)n2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
66774229 144724 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 10 1 3 6.3 COc1ccccc1C(=O)N(CCCc1ccccc1)Cc1ccc(-c2ccccc2C(=O)O)cc1 10.1021/acsmedchemlett.6b00225
CHEMBL3912909 144724 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 10 1 3 6.3 COc1ccccc1C(=O)N(CCCc1ccccc1)Cc1ccc(-c2ccccc2C(=O)O)cc1 10.1021/acsmedchemlett.6b00225
73336083 113496 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 397 6 1 9 2.4 COc1cc(OC)c(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)cc1OC 10.1016/j.bmcl.2014.08.001
CHEMBL3326529 113496 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 397 6 1 9 2.4 COc1cc(OC)c(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)cc1OC 10.1016/j.bmcl.2014.08.001
66861497 162288 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 466 13 2 6 4.6 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2cc(CCC(=O)O)cn2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4172946 162288 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 466 13 2 6 4.6 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2cc(CCC(=O)O)cn2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
71461120 82686 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 500 7 2 6 5.8 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1F 10.1021/jm301022v
CHEMBL2182030 82686 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 500 7 2 6 5.8 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1F 10.1021/jm301022v
71457480 82701 0 None 2 2 Human 6.5 pIC50 = 6.5 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 550 7 2 6 6.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
CHEMBL2182046 82701 0 None 2 2 Human 6.5 pIC50 = 6.5 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 550 7 2 6 6.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
70819507 82711 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 455 7 2 5 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)cnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182061 82711 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 455 7 2 5 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)cnn1C)c1ccccc1 10.1021/jm301022v
70819486 82707 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 355 4 1 4 5.1 CC(OC(=O)Nc1c(-c2ccccc2)cnn1C)c1ccccc1Cl 10.1021/jm301022v
CHEMBL2182056 82707 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 355 4 1 4 5.1 CC(OC(=O)Nc1c(-c2ccccc2)cnn1C)c1ccccc1Cl 10.1021/jm301022v
71267051 82696 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 468 7 2 6 5.4 C[C@@H](OC(=O)Nc1cnnn1-c1ccc(-c2ccc(C3(C(=O)O)CC3)cc2)cc1)c1ccccc1 10.1021/jm301022v
CHEMBL2182040 82696 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 468 7 2 6 5.4 C[C@@H](OC(=O)Nc1cnnn1-c1ccc(-c2ccc(C3(C(=O)O)CC3)cc2)cc1)c1ccccc1 10.1021/jm301022v
44441096 93189 0 None -3 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 470 9 2 5 6.7 CC(OC(=O)Nc1conc1-c1ccc(CCC(C)(C)CC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246734 93189 0 None -3 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 470 9 2 5 6.7 CC(OC(=O)Nc1conc1-c1ccc(CCC(C)(C)CC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
66774362 152921 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 509 11 1 4 6.3 COc1ccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)cc1OC 10.1021/acsmedchemlett.6b00225
CHEMBL3979511 152921 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 509 11 1 4 6.3 COc1ccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)cc1OC 10.1021/acsmedchemlett.6b00225
71462859 82681 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 433 7 2 5 5.2 CC[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C 10.1021/jm301022v
CHEMBL2182024 82681 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 433 7 2 5 5.2 CC[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C 10.1021/jm301022v
66861902 162218 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 471 13 2 6 5.3 COc1cc([C@@H](O)[C@@H](CCCc2ccsc2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4171981 162218 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 471 13 2 6 5.3 COc1cc([C@@H](O)[C@@H](CCCc2ccsc2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
71453960 82697 0 None 162 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 456 7 2 6 5.1 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182042 82697 0 None 162 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 456 7 2 6 5.1 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
23079111 149492 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 539 12 1 5 6.4 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)cc(OC)c1OC 10.1021/acsmedchemlett.6b00225
CHEMBL3950523 149492 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 539 12 1 5 6.4 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)cc(OC)c1OC 10.1021/acsmedchemlett.6b00225
71461124 82708 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 373 4 1 4 5.2 CC(OC(=O)Nc1c(-c2ccc(F)cc2)cnn1C)c1ccccc1Cl 10.1021/jm301022v
CHEMBL2182057 82708 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 373 4 1 4 5.2 CC(OC(=O)Nc1c(-c2ccc(F)cc2)cnn1C)c1ccccc1Cl 10.1021/jm301022v
71450321 82690 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 434 7 2 6 4.7 CC[C@@H](C)OC(=O)Nc1c(C)nnn1-c1ccc(-c2ccc(C3(C(=O)O)CC3)cc2)cc1 10.1021/jm301022v
CHEMBL2182034 82690 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 434 7 2 6 4.7 CC[C@@H](C)OC(=O)Nc1c(C)nnn1-c1ccc(-c2ccc(C3(C(=O)O)CC3)cc2)cc1 10.1021/jm301022v
142610742 169456 0 None - 1 Human 8.4 pIC50 = 8.4 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 499 10 2 7 3.7 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNS(=O)(=O)CCc1ccccc1 10.1021/acsmedchemlett.9b00429
CHEMBL4442789 169456 0 None - 1 Human 8.4 pIC50 = 8.4 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 499 10 2 7 3.7 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNS(=O)(=O)CCc1ccccc1 10.1021/acsmedchemlett.9b00429
66861761 161605 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 466 13 2 6 4.6 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CCC(=O)O)n2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4162273 161605 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 466 13 2 6 4.6 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CCC(=O)O)n2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
71462858 82680 0 None 11 2 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 549 7 2 5 7.2 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
CHEMBL2182023 82680 0 None 11 2 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 549 7 2 5 7.2 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
134148024 149137 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccc(C)cc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3947597 149137 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccc(C)cc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
71459353 82695 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 496 8 2 6 5.9 CCc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
CHEMBL2182039 82695 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 496 8 2 6 5.9 CCc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
44325312 205212 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 599 23 3 4 8.2 CCCCC/C=C\C/C=C\CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL91168 205212 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 599 23 3 4 8.2 CCCCC/C=C\C/C=C\CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
11340921 92882 0 None -5 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 496 9 2 7 5.4 CC(OC(=O)Nc1conc1-c1ccc(CSCCS(=O)(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL245295 92882 0 None -5 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 496 9 2 7 5.4 CC(OC(=O)Nc1conc1-c1ccc(CSCCS(=O)(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
66775156 143603 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 10 1 3 6.3 COc1ccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)cc1 10.1021/acsmedchemlett.6b00225
CHEMBL3903904 143603 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 10 1 3 6.3 COc1ccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)cc1 10.1021/acsmedchemlett.6b00225
72704618 159356 0 None 4 2 Human 5.4 pIC50 = 5.4 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3cccc(C4(C(=O)O)CC4)c3)cc2)nnn1C)c1ccccc1 nan
CHEMBL4107074 159356 0 None 4 2 Human 5.4 pIC50 = 5.4 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3cccc(C4(C(=O)O)CC4)c3)cc2)nnn1C)c1ccccc1 nan
66862949 162435 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 471 13 2 6 5.3 COc1cc([C@@H](O)[C@@H](CCCc2cccs2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4175424 162435 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 471 13 2 6 5.3 COc1cc([C@@H](O)[C@@H](CCCc2cccs2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
10367662 2146 82 None -1 5 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assayAntagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmc.2009.12.020
2907 2146 82 None -1 5 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assayAntagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmc.2009.12.020
CHEMBL361501 2146 82 None -1 5 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assayAntagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmc.2009.12.020
72704617 151707 0 None 6 2 Human 7.3 pIC50 = 7.3 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 550 7 2 6 6.6 CC(OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
CHEMBL3969018 151707 0 None 6 2 Human 7.3 pIC50 = 7.3 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 550 7 2 6 6.6 CC(OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
66775340 161938 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 460 12 1 4 5.7 COc1cc(C(=O)C(CCCc2ccccc2)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4167471 161938 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 460 12 1 4 5.7 COc1cc(C(=O)C(CCCc2ccccc2)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
11374611 93231 0 None 4 2 Rat 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246929 93231 0 None 4 2 Rat 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
71453960 82697 0 None 162 2 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 456 7 2 6 5.1 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182042 82697 0 None 162 2 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 456 7 2 6 5.1 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
71453960 82697 0 None 162 2 Human 7.3 pIC50 = 7.3 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 456 7 2 6 5.1 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)nnn1C)c1ccccc1 nan
CHEMBL2182042 82697 0 None 162 2 Human 7.3 pIC50 = 7.3 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 456 7 2 6 5.1 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)nnn1C)c1ccccc1 nan
155153676 174028 0 None - 1 Human 8.3 pIC50 = 8.3 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 483 8 2 7 4.6 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNC(=O)OCc1cccc(F)c1 10.1021/acsmedchemlett.9b00429
CHEMBL4557434 174028 0 None - 1 Human 8.3 pIC50 = 8.3 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 483 8 2 7 4.6 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNC(=O)OCc1cccc(F)c1 10.1021/acsmedchemlett.9b00429
66775301 152625 0 None - 1 Human 8.2 pIC50 = 8.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 573 12 1 5 7.4 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cc(Cl)ccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3976876 152625 0 None - 1 Human 8.2 pIC50 = 8.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 573 12 1 5 7.4 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cc(Cl)ccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
44454369 155062 0 None 239 2 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 expressed in RH7777 cells with Gi4-protein and aequorin by calcium mobilization assayAntagonist activity at LPA1 expressed in RH7777 cells with Gi4-protein and aequorin by calcium mobilization assay
ChEMBL 322 4 1 4 5.0 Cc1noc(-c2ccccc2)c1NC(=O)OC(C)c1ccccc1 10.1016/j.bmcl.2007.12.024
CHEMBL404575 155062 0 None 239 2 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 expressed in RH7777 cells with Gi4-protein and aequorin by calcium mobilization assayAntagonist activity at LPA1 expressed in RH7777 cells with Gi4-protein and aequorin by calcium mobilization assay
ChEMBL 322 4 1 4 5.0 Cc1noc(-c2ccccc2)c1NC(=O)OC(C)c1ccccc1 10.1016/j.bmcl.2007.12.024
73336085 113499 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 381 5 1 8 2.8 COc1ccc(C(=O)/C(=N\C2CCCCC2)n2ncc(C#N)c2N)c(OC)c1 10.1016/j.bmcl.2014.08.001
CHEMBL3326533 113499 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 381 5 1 8 2.8 COc1ccc(C(=O)/C(=N\C2CCCCC2)n2ncc(C#N)c2N)c(OC)c1 10.1016/j.bmcl.2014.08.001
10367662 2146 82 None -1 5 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmcl.2007.04.024
2907 2146 82 None -1 5 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmcl.2007.04.024
CHEMBL361501 2146 82 None -1 5 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmcl.2007.04.024
66862428 161547 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 480 12 2 6 4.8 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2nc(C)c(CC(=O)O)c2C)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4161219 161547 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 480 12 2 6 4.8 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2nc(C)c(CC(=O)O)c2C)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
5311306 96087 2 None 1 2 Human 5.3 pIC50 = 5.3 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL262906 96087 2 None 1 2 Human 5.3 pIC50 = 5.3 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
66774976 145881 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 467 9 1 2 6.5 O=C(O)c1ccccc1-c1ccc(CN(CCCc2ccccc2)C(=O)c2cccc(F)c2)cc1 10.1021/acsmedchemlett.6b00225
CHEMBL3921894 145881 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 467 9 1 2 6.5 O=C(O)c1ccccc1-c1ccc(CN(CCCc2ccccc2)C(=O)c2cccc(F)c2)cc1 10.1021/acsmedchemlett.6b00225
10051843 1396 1 None -24 2 Human 5.3 pIC50 = 5.3 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 504 20 3 8 4.4 CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC)COP(=O)(OP(=O)(O)O)O 10.1021/jm049609r
2916 1396 1 None -24 2 Human 5.3 pIC50 = 5.3 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 504 20 3 8 4.4 CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC)COP(=O)(OP(=O)(O)O)O 10.1021/jm049609r
CHEMBL191055 1396 1 None -24 2 Human 5.3 pIC50 = 5.3 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 504 20 3 8 4.4 CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC)COP(=O)(OP(=O)(O)O)O 10.1021/jm049609r
11305821 93240 0 None 3 2 Rat 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 464 9 2 6 6.1 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCCC1 10.1016/j.bmcl.2007.04.024
CHEMBL246943 93240 0 None 3 2 Rat 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 464 9 2 6 6.1 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCCC1 10.1016/j.bmcl.2007.04.024
11599847 204999 0 None -8 2 Human 5.3 pIC50 = 5.3 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL89937 204999 0 None -8 2 Human 5.3 pIC50 = 5.3 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
71452131 82714 0 None 144 2 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 499 7 2 5 6.3 CC(OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccc(F)cc1 10.1021/jm301022v
CHEMBL2182065 82714 0 None 144 2 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 499 7 2 5 6.3 CC(OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccc(F)cc1 10.1021/jm301022v
71457482 82705 0 None 165 2 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 462 7 2 6 5.5 C[C@@H](OC(=O)Nc1c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182051 82705 0 None 165 2 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 462 7 2 6 5.5 C[C@@H](OC(=O)Nc1c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
71457482 82705 0 None 165 2 Human 7.2 pIC50 = 7.2 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 462 7 2 6 5.5 C[C@@H](OC(=O)Nc1c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nnn1C)c1ccccc1 nan
CHEMBL2182051 82705 0 None 165 2 Human 7.2 pIC50 = 7.2 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 462 7 2 6 5.5 C[C@@H](OC(=O)Nc1c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nnn1C)c1ccccc1 nan
73335984 113493 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 335 4 1 6 3.0 CCc1ccc(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)cc1 10.1016/j.bmcl.2014.08.001
CHEMBL3326524 113493 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 335 4 1 6 3.0 CCc1ccc(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)cc1 10.1016/j.bmcl.2014.08.001
56943915 123175 5 None - 1 Human 8.2 pIC50 = 8.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated with protein followed by LPA induction measured for 2 mins by Fluo-4 dye-based FLIPR assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated with protein followed by LPA induction measured for 2 mins by Fluo-4 dye-based FLIPR assay
ChEMBL 549 11 2 8 3.0 COc1ccc([C@@H](O)C(=O)N(CCCc2ccccc2)Cc2nc(C(=O)NS(C)(=O)=O)c(C)s2)c(F)c1 10.1039/C4MD00333K
CHEMBL3621968 123175 5 None - 1 Human 8.2 pIC50 = 8.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated with protein followed by LPA induction measured for 2 mins by Fluo-4 dye-based FLIPR assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated with protein followed by LPA induction measured for 2 mins by Fluo-4 dye-based FLIPR assay
ChEMBL 549 11 2 8 3.0 COc1ccc([C@@H](O)C(=O)N(CCCc2ccccc2)Cc2nc(C(=O)NS(C)(=O)=O)c(C)s2)c(F)c1 10.1039/C4MD00333K
132191124 157161 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAntagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 484 4 1 4 4.2 O=C(Nc1cc(F)c(Cl)c(F)c1)c1cc(S(=O)(=O)N2CCOCC2)c(Cl)cc1Cl 10.1021/acs.jmedchem.6b01270
CHEMBL4082022 157161 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAntagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 484 4 1 4 4.2 O=C(Nc1cc(F)c(Cl)c(F)c1)c1cc(S(=O)(=O)N2CCOCC2)c(Cl)cc1Cl 10.1021/acs.jmedchem.6b01270
44325682 106400 1 None 1 2 Human 6.2 pIC50 = 6.2 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL314555 106400 1 None 1 2 Human 6.2 pIC50 = 6.2 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
753410 200262 9 None 4 2 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 311 4 1 4 2.5 Cc1ccc(Oc2ccc3c(c2)C(=O)N(CC(=O)O)C3=O)cc1 10.1016/j.bmc.2009.09.022
CHEMBL607806 200262 9 None 4 2 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 311 4 1 4 2.5 Cc1ccc(Oc2ccc3c(c2)C(=O)N(CC(=O)O)C3=O)cc1 10.1016/j.bmc.2009.09.022
58902982 161449 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 462 12 2 4 5.6 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4159560 161449 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 462 12 2 4 5.6 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
11351723 161947 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 463 10 2 5 4.6 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4167552 161947 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 463 10 2 5 4.6 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
150336102 171498 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 499 9 2 7 4.0 Cc1nc(-c2onc(C)c2CNS(=O)(=O)Cc2ccccc2)ccc1O[C@H]1CCC[C@H](C(=O)O)C1 10.1021/acsmedchemlett.9b00429
CHEMBL4472223 171498 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 499 9 2 7 4.0 Cc1nc(-c2onc(C)c2CNS(=O)(=O)Cc2ccccc2)ccc1O[C@H]1CCC[C@H](C(=O)O)C1 10.1021/acsmedchemlett.9b00429
71462863 82709 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 373 4 1 4 5.2 C[C@@H](OC(=O)Nc1c(-c2ccccc2F)cnn1C)c1ccccc1Cl 10.1021/jm301022v
CHEMBL2182058 82709 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 373 4 1 4 5.2 C[C@@H](OC(=O)Nc1c(-c2ccccc2F)cnn1C)c1ccccc1Cl 10.1021/jm301022v
66775150 149793 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 491 13 1 5 5.1 COc1cc(C(=O)N(CCCCc2ccccc2)Cc2ccc(OCC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3953068 149793 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 491 13 1 5 5.1 COc1cc(C(=O)N(CCCCc2ccccc2)Cc2ccc(OCC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
66773671 144741 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 491 13 1 5 5.3 COc1cc(C(=O)N(CCCOc2cccc(C(=O)O)c2)CCCc2ccccc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3913038 144741 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 491 13 1 5 5.3 COc1cc(C(=O)N(CCCOc2cccc(C(=O)O)c2)CCCc2ccccc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
71457479 82700 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 448 7 2 6 4.9 CC(C)[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C 10.1021/jm301022v
CHEMBL2182045 82700 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 448 7 2 6 4.9 CC(C)[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C 10.1021/jm301022v
71457479 82700 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 448 7 2 6 4.9 CC(C)[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C nan
CHEMBL2182045 82700 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 448 7 2 6 4.9 CC(C)[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C nan
44325681 106399 0 None -2 2 Human 5.2 pIC50 = 5.2 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 626 23 4 4 9.1 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(Oc2cc3ccccc3[nH]2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL314554 106399 0 None -2 2 Human 5.2 pIC50 = 5.2 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 626 23 4 4 9.1 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(Oc2cc3ccccc3[nH]2)cc1 10.1016/j.bmcl.2004.03.076
66774888 151991 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 539 12 1 5 6.8 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3971582 151991 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 539 12 1 5 6.8 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
44441093 93138 0 None 2 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 442 9 2 5 6.1 CC(OC(=O)Nc1conc1-c1ccc(CCCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246527 93138 0 None 2 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 442 9 2 5 6.1 CC(OC(=O)Nc1conc1-c1ccc(CCCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
11167018 93190 0 None 1 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 457 8 3 6 5.1 CC(OC(=O)Nc1conc1-c1ccc(NC(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246735 93190 0 None 1 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 457 8 3 6 5.1 CC(OC(=O)Nc1conc1-c1ccc(NC(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
11340921 92882 0 None 5 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 496 9 2 7 5.4 CC(OC(=O)Nc1conc1-c1ccc(CSCCS(=O)(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL245295 92882 0 None 5 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 496 9 2 7 5.4 CC(OC(=O)Nc1conc1-c1ccc(CSCCS(=O)(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
73336082 113495 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 355 4 1 7 2.6 COc1ccc(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)c(F)c1 10.1016/j.bmcl.2014.08.001
CHEMBL3326527 113495 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 355 4 1 7 2.6 COc1ccc(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)c(F)c1 10.1016/j.bmcl.2014.08.001
10367662 2146 82 None -1 5 Human 6.1 pIC50 = 6.1 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/jm049609r
2907 2146 82 None -1 5 Human 6.1 pIC50 = 6.1 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/jm049609r
CHEMBL361501 2146 82 None -1 5 Human 6.1 pIC50 = 6.1 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/jm049609r
73332314 113492 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 367 5 1 8 2.4 COc1ccc(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)c(OC)c1 10.1016/j.bmcl.2014.08.001
CHEMBL3326523 113492 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 367 5 1 8 2.4 COc1ccc(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)c(OC)c1 10.1016/j.bmcl.2014.08.001
44325214 205438 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 463 15 3 4 4.8 CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL92452 205438 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 463 15 3 4 4.8 CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
11849496 79181 0 None 2 2 Human 6.1 pIC50 = 6.1 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 406 16 1 4 6.1 CCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
CHEMBL211465 79181 0 None 2 2 Human 6.1 pIC50 = 6.1 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 406 16 1 4 6.1 CCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
10367662 2146 82 None -1 5 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assayAntagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/acs.jmedchem.2c00046
2907 2146 82 None -1 5 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assayAntagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/acs.jmedchem.2c00046
CHEMBL361501 2146 82 None -1 5 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assayAntagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/acs.jmedchem.2c00046
73336084 113497 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 387 4 1 7 3.6 COc1cc2ccccc2cc1C(=O)/C(=N\C1CCCC1)n1ncc(C#N)c1N 10.1016/j.bmcl.2014.08.001
CHEMBL3326531 113497 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 387 4 1 7 3.6 COc1cc2ccccc2cc1C(=O)/C(=N\C1CCCC1)n1ncc(C#N)c1N 10.1016/j.bmcl.2014.08.001
44441080 93230 0 None 3 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1cnoc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246928 93230 0 None 3 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1cnoc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
73335987 113498 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 377 4 1 7 2.9 COc1cc2c(cc1C(=O)/C(=N\C1CCCC1)n1ncc(C#N)c1N)CCC2 10.1016/j.bmcl.2014.08.001
CHEMBL3326532 113498 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 377 4 1 7 2.9 COc1cc2c(cc1C(=O)/C(=N\C1CCCC1)n1ncc(C#N)c1N)CCC2 10.1016/j.bmcl.2014.08.001
11317548 161808 7 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4165205 161808 7 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4175820 161808 7 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
9958483 97375 0 None -2 2 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 525 12 1 5 6.5 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL272087 97375 0 None -2 2 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 525 12 1 5 6.5 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
152069844 169458 0 None - 1 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 483 8 2 7 4.6 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNC(=O)OCc1ccc(F)cc1 10.1021/acsmedchemlett.9b00429
CHEMBL4442819 169458 0 None - 1 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 483 8 2 7 4.6 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNC(=O)OCc1ccc(F)cc1 10.1021/acsmedchemlett.9b00429
44325235 167533 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 547 21 3 4 7.1 CCCCCCCCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL432821 167533 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 547 21 3 4 7.1 CCCCCCCCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
1365686 199713 31 None 5 3 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 404 5 1 6 3.9 O=C(O)c1ccc2c(c1)C(=O)N(c1cccc(Oc3ccc([N+](=O)[O-])cc3)c1)C2=O 10.1016/j.bmc.2009.09.022
CHEMBL604677 199713 31 None 5 3 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 404 5 1 6 3.9 O=C(O)c1ccc2c(c1)C(=O)N(c1cccc(Oc3ccc([N+](=O)[O-])cc3)c1)C2=O 10.1016/j.bmc.2009.09.022
16043259 79384 0 None 1 2 Human 6.0 pIC50 = 6.0 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 434 18 1 4 6.9 CCCCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
CHEMBL212029 79384 0 None 1 2 Human 6.0 pIC50 = 6.0 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 434 18 1 4 6.9 CCCCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
71461121 82692 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 434 5 2 6 4.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC(C)(C)C 10.1021/jm301022v
CHEMBL2182036 82692 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 434 5 2 6 4.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC(C)(C)C 10.1021/jm301022v
44325401 105625 0 None -1 2 Human 6.9 pKi = 6.9 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 627 23 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OC2Cc3ccccc3C2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL313413 105625 0 None -1 2 Human 6.9 pKi = 6.9 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 627 23 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OC2Cc3ccccc3C2)cc1 10.1016/j.bmcl.2004.03.076
2260227 183495 9 None -3090 3 Human 4.9 pKi = 4.9 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 488 10 4 6 4.4 O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1 10.1016/j.bmc.2008.04.035
CHEMBL482498 183495 9 None -3090 3 Human 4.9 pKi = 4.9 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 488 10 4 6 4.4 O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1 10.1016/j.bmc.2008.04.035
5311306 96087 2 None 1 2 Human 6.9 pKi = 6.9 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL262906 96087 2 None 1 2 Human 6.9 pKi = 6.9 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
23725184 108767 1 None - 0 Human 6.8 pKi = 6.8 Functional
Competitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation countingCompetitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation counting
ChEMBL 670 24 3 5 8.8 CCCCCCCCCCCCCCCC(=O)N[C@@H](/C=C/P(=O)(O)O)Cc1ccc(OCc2cc(OCC(F)(F)F)ccn2)cc1 10.1039/c0md00273a
CHEMBL3218460 108767 1 None - 0 Human 6.8 pKi = 6.8 Functional
Competitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation countingCompetitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation counting
ChEMBL 670 24 3 5 8.8 CCCCCCCCCCCCCCCC(=O)N[C@@H](/C=C/P(=O)(O)O)Cc1ccc(OCc2cc(OCC(F)(F)F)ccn2)cc1 10.1039/c0md00273a
44325682 106400 1 None 1 2 Human 6.8 pKi = 6.8 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL314555 106400 1 None 1 2 Human 6.8 pKi = 6.8 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
16725999 720 1 None -9 2 Human 6.8 pKi = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assayAntagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assay
ChEMBL 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O 10.1039/C4MD00255E
6985 720 1 None -9 2 Human 6.8 pKi = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assayAntagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assay
ChEMBL 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O 10.1039/C4MD00255E
CHEMBL3621357 720 1 None -9 2 Human 6.8 pKi = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assayAntagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assay
ChEMBL 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O 10.1039/C4MD00255E
87470750 123286 0 None - 0 Human 6.8 pKi = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assayAntagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assay
ChEMBL 512 20 3 4 6.2 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)CC(Br)P(=O)(O)O 10.1039/C4MD00255E
CHEMBL3621353 123286 0 None - 0 Human 6.8 pKi = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assayAntagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assay
ChEMBL 512 20 3 4 6.2 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)CC(Br)P(=O)(O)O 10.1039/C4MD00255E
CHEMBL3623936 123286 0 None - 0 Human 6.8 pKi = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assayAntagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assay
ChEMBL 512 20 3 4 6.2 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)CC(Br)P(=O)(O)O 10.1039/C4MD00255E
10393842 168622 0 None 1 2 Human 7.8 pKi = 7.8 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL440696 168622 0 None 1 2 Human 7.8 pKi = 7.8 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
11849496 79181 0 None 2 2 Human 6.5 pKi = 6.5 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 406 16 1 4 6.1 CCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
CHEMBL211465 79181 0 None 2 2 Human 6.5 pKi = 6.5 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 406 16 1 4 6.1 CCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
44325391 205192 0 None -30 2 Human 7.5 pKi = 7.5 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL91058 205192 0 None -30 2 Human 7.5 pKi = 7.5 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
11599847 204999 0 None -8 2 Human 6.5 pKi = 6.5 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL89937 204999 0 None -8 2 Human 6.5 pKi = 6.5 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
16043259 79384 0 None 1 2 Human 6.4 pKi = 6.4 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 434 18 1 4 6.9 CCCCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
CHEMBL212029 79384 0 None 1 2 Human 6.4 pKi = 6.4 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 434 18 1 4 6.9 CCCCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
744590 190632 27 None -10 2 Human 7.3 pKi = 7.3 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 304 6 4 4 0.8 O=C(O)/C=C/C(=O)Nc1cccc(NC(=O)/C=C/C(=O)O)c1 10.1016/j.bmc.2008.04.035
CHEMBL519002 190632 27 None -10 2 Human 7.3 pKi = 7.3 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 304 6 4 4 0.8 O=C(O)/C=C/C(=O)Nc1cccc(NC(=O)/C=C/C(=O)O)c1 10.1016/j.bmc.2008.04.035
44414925 77713 0 None 72 2 Human 7.2 pKi = 7.2 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 436 18 1 4 7.1 CCCCCCCCCCCCCCCCCC(=O)OC[C@@H]1CC(F)P(=O)(O)O1 10.1021/jm060351+
CHEMBL210117 77713 0 None 72 2 Human 7.2 pKi = 7.2 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 436 18 1 4 7.1 CCCCCCCCCCCCCCCCCC(=O)OC[C@@H]1CC(F)P(=O)(O)O1 10.1021/jm060351+
44325681 106399 0 None -2 2 Human 7.1 pKi = 7.1 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 626 23 4 4 9.1 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(Oc2cc3ccccc3[nH]2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL314554 106399 0 None -2 2 Human 7.1 pKi = 7.1 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 626 23 4 4 9.1 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(Oc2cc3ccccc3[nH]2)cc1 10.1016/j.bmcl.2004.03.076
90665720 108766 0 None - 0 Human 7.1 pKi = 7.1 Functional
Competitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation countingCompetitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation counting
ChEMBL 702 27 3 6 9.0 CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2cc(OCC(F)(F)F)ccn2)cc1 10.1039/c0md00273a
CHEMBL3218459 108766 0 None - 0 Human 7.1 pKi = 7.1 Functional
Competitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation countingCompetitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation counting
ChEMBL 702 27 3 6 9.0 CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2cc(OCC(F)(F)F)ccn2)cc1 10.1039/c0md00273a
2913 344 0 None -8 2 Human 6.2 pEC50 = 6.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC 16892372
56947064 344 0 None -8 2 Human 6.2 pEC50 = 6.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC 16892372
CHEMBL3621962 344 0 None -8 2 Human 6.2 pEC50 = 6.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC 16892372
11314 1174 0 None -25 3 Human 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 275 6 1 3 3.7 CCN([C@H](c1cccc2c1oc(c2C)CC)CO)CC 32409422
154733035 1174 0 None -25 3 Human 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 275 6 1 3 3.7 CCN([C@H](c1cccc2c1oc(c2C)CC)CO)CC 32409422
10074712 3651 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 18781939
10074712 3651 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 20729877
23701997 3651 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 18781939
23701997 3651 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 20729877
6984 3651 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 18781939
6984 3651 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 20729877
73755252 3651 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 18781939
73755252 3651 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 20729877
10587 3833 1 None - 1 Human 6.6 pEC50 = 6.6 Functional
UnclassifiedUnclassified
Guide to Pharmacology 464 15 2 4 4.8 BrC[C@@H](OC(=O)CCCCCCCCCc1ccccc1)COP(=O)(O)O 31790581
145996523 3833 1 None - 1 Human 6.6 pEC50 = 6.6 Functional
UnclassifiedUnclassified
Guide to Pharmacology 464 15 2 4 4.8 BrC[C@@H](OC(=O)CCCCCCCCCc1ccccc1)COP(=O)(O)O 31790581
CHEMBL4646737 3833 1 None - 1 Human 6.6 pEC50 = 6.6 Functional
UnclassifiedUnclassified
Guide to Pharmacology 464 15 2 4 4.8 BrC[C@@H](OC(=O)CCCCCCCCCc1ccccc1)COP(=O)(O)O 31790581
2936 85 0 None -19 4 Human 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC(COP(=O)(O)O)CO 10922489
56947016 85 0 None -19 4 Human 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC(COP(=O)(O)O)CO 10922489
17757220 2663 0 None -6 3 Mouse 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 405 19 3 3 5.2 CCCCCCCC/C=C/CCCCCCCC(=O)NCCOP(=O)(O)O 18781939
6982 2663 0 None -6 3 Mouse 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 405 19 3 3 5.2 CCCCCCCC/C=C/CCCCCCCC(=O)NCCOP(=O)(O)O 18781939
CHEMBL1574292 2663 0 None -6 3 Mouse 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 405 19 3 3 5.2 CCCCCCCC/C=C/CCCCCCCC(=O)NCCOP(=O)(O)O 18781939
6983 2863 0 None 1 4 Human 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 907 48 0 7 19.6 CCCCCCCC/C=C\CCCCCCCC(=O)OP(=O)(SC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC 16033271
6983 2863 0 None -1 4 Mouse 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 907 48 0 7 19.6 CCCCCCCC/C=C\CCCCCCCC(=O)OP(=O)(SC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC 20729877
73755251 2863 0 None 1 4 Human 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 907 48 0 7 19.6 CCCCCCCC/C=C\CCCCCCCC(=O)OP(=O)(SC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC 16033271
73755251 2863 0 None -1 4 Mouse 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 907 48 0 7 19.6 CCCCCCCC/C=C\CCCCCCCC(=O)OP(=O)(SC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC 20729877
11313 1172 0 None 1 3 Human 7.5 pEC50 = 7.5 Functional
UnclassifiedUnclassified
Guide to Pharmacology 261 5 1 3 3.4 CCN([C@H](c1cccc2c1oc(c2C)C)CO)CC 32409422
154733034 1172 0 None 1 3 Human 7.5 pEC50 = 7.5 Functional
UnclassifiedUnclassified
Guide to Pharmacology 261 5 1 3 3.4 CCN([C@H](c1cccc2c1oc(c2C)C)CO)CC 32409422
2906 2313 14 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 18781939
2906 2313 14 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 20505096
2906 2313 14 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 8922387
5395 2313 14 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 18781939
5395 2313 14 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 20505096
5395 2313 14 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 8922387
5497152 2313 14 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 18781939
5497152 2313 14 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 20505096
5497152 2313 14 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 8922387
CHEMBL1222042 2313 14 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 18781939
CHEMBL1222042 2313 14 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 20505096
CHEMBL1222042 2313 14 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 8922387
2905 386 41 None 1 7 Mouse 7.7 pEC50 None 7.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 490 7 2 5 6.9 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C 20649573
46240292 386 41 None 1 7 Mouse 7.7 pEC50 None 7.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 490 7 2 5 6.9 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C 20649573
CHEMBL3621966 386 41 None 1 7 Mouse 7.7 pEC50 None 7.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 490 7 2 5 6.9 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C 20649573
11785732 2884 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
FLIPR intracellular calcium mobilisation assayFLIPR intracellular calcium mobilisation assay
Guide to Pharmacology 521 11 2 7 4.4 COC(=O)c1cn(cc1CC(=O)O)C[C@@H]([C@@H](c1cc(OC)c(c(c1)OC)C)O)CC1Cc2c(C1)cccc2 26091040
8589 2884 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
FLIPR intracellular calcium mobilisation assayFLIPR intracellular calcium mobilisation assay
Guide to Pharmacology 521 11 2 7 4.4 COC(=O)c1cn(cc1CC(=O)O)C[C@@H]([C@@H](c1cc(OC)c(c(c1)OC)C)O)CC1Cc2c(C1)cccc2 26091040
8590 2885 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
FLIPR intracellular calcium mobilisation assayFLIPR intracellular calcium mobilisation assay
Guide to Pharmacology 563 13 2 8 4.7 COC(=O)c1cn(cc1CCC(=O)O)C[C@@H]([C@@H](c1cc(OC)c(c(c1)OC)C(=O)C)O)CC1Cc2c(C1)cccc2 26091040
91799237 2885 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
FLIPR intracellular calcium mobilisation assayFLIPR intracellular calcium mobilisation assay
Guide to Pharmacology 563 13 2 8 4.7 COC(=O)c1cn(cc1CCC(=O)O)C[C@@H]([C@@H](c1cc(OC)c(c(c1)OC)C(=O)C)O)CC1Cc2c(C1)cccc2 26091040
8588 2876 0 None - 1 Human 8.0 pIC50 = 8.0 Functional
FLIPR intracellular calcium mobilisation assayFLIPR intracellular calcium mobilisation assay
Guide to Pharmacology 518 11 2 6 4.8 COc1cc(cc(c1C)OC)[C@H]([C@@H](OC1Cc2c(C1)cccc2)COc1ccc(cc1)C1(CC1)C(=O)O)O 26091040
91799238 2876 0 None - 1 Human 8.0 pIC50 = 8.0 Functional
FLIPR intracellular calcium mobilisation assayFLIPR intracellular calcium mobilisation assay
Guide to Pharmacology 518 11 2 6 4.8 COc1cc(cc(c1C)OC)[C@H]([C@@H](OC1Cc2c(C1)cccc2)COc1ccc(cc1)C1(CC1)C(=O)O)O 26091040
16725999 720 1 None -9 2 Human 5.3 pIC50 = 5.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O 19509223
6985 720 1 None -9 2 Human 5.3 pIC50 = 5.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O 19509223
CHEMBL3621357 720 1 None -9 2 Human 5.3 pIC50 = 5.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O 19509223
24771260 425 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@@H](P(=O)(O)O)Br)O 19509223
6987 425 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@@H](P(=O)(O)O)Br)O 19509223
CHEMBL3621356 425 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@@H](P(=O)(O)O)Br)O 19509223
46213949 370 39 None 5 2 Human 6.1 pIC50 = 6.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 21159750
6988 370 39 None 5 2 Human 6.1 pIC50 = 6.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 21159750
CHEMBL2182052 370 39 None 5 2 Human 6.1 pIC50 = 6.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 21159750
46213949 370 39 None -5 2 Mouse 6.1 pIC50 = 6.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 21159750
6988 370 39 None -5 2 Mouse 6.1 pIC50 = 6.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 21159750
CHEMBL2182052 370 39 None -5 2 Mouse 6.1 pIC50 = 6.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 21159750
24771259 3647 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@H](P(=O)(O)O)Br)O 19509223
6986 3647 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@H](P(=O)(O)O)Br)O 19509223
CHEMBL3621355 3647 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@H](P(=O)(O)O)Br)O 19509223
10367662 2146 82 None -1 5 Mouse 6.8 pIC50 = 6.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 14500756
2907 2146 82 None -1 5 Mouse 6.8 pIC50 = 6.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 14500756
CHEMBL361501 2146 82 None -1 5 Mouse 6.8 pIC50 = 6.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 14500756
66775043 2879 29 None 53 2 Human 6.8